Synairgen (LON:SNG) Shares Up 4.4% – What’s Next?

Synairgen plc (LON:SNG)’s share price was up 4.4% during trading on Wednesday . The stock traded as high as GBX 2.03 ($0.03) and last traded at GBX 2.03 ($0.03). Approximately 228,663 shares changed hands during trading, a decline of 89% from the average daily volume of 2,145,702 shares. The stock had previously closed at GBX 1.95 ($0.02).

Synairgen Stock Performance

The stock has a market cap of £4.05 million, a PE ratio of -67.00 and a beta of -2.23. The stock has a fifty day simple moving average of GBX 2.86 and a two-hundred day simple moving average of GBX 3.69. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).